NOVARTIS logo.jpg
Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event
22 sept. 2022 01h15 HE | Novartis Pharma AG
Transformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the US Advancing eight...
NOVARTIS logo.jpg
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
21 sept. 2022 01h00 HE | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its...
sandoz-logo.jpg
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial  
19 sept. 2022 01h15 HE | Novartis Pharma AG
ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in...
NOVARTIS logo.jpg
Novartis statement regarding competition authority investigation into assertion of a patent
15 sept. 2022 01h30 HE | Novartis Pharma AG
Company confident to clarify legitimacy of its position and fully cooperating with authorities Basel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss Competition...
NOVARTIS logo.jpg
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
10 sept. 2022 02h30 HE | Novartis Pharma AG
Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and...
NOVARTIS logo.jpg
Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer
09 sept. 2022 01h15 HE | Novartis Pharma AG
New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to ET alone, in HR+/HER2- aBC patients with...
NOVARTIS logo.jpg
Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses
02 sept. 2022 01h15 HE | Novartis Pharma AG
Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of...
NOVARTIS logo.jpg
Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis
01 sept. 2022 01h00 HE | Novartis Pharma AG
After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr....
NOVARTIS logo.jpg
Novartis presents new data in breast and prostate cancer at ESMO
30 août 2022 01h15 HE | Novartis Pharma AG
Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali® Data from VISION study reporting...
NOVARTIS logo.jpg
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
25 août 2022 01h00 HE | Novartis Pharma AG
 Ad hoc announcement pursuant to Art. 53 LR  Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1...